Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Euthymics pays $2mm cash for struggling Dov Pharmaceuticals

Executive Summary

Private neurology biotech Euthymics Bioscience signed a letter of intent to merge with publicly traded Dov Pharmaceutical (cardiovascular and CNS diseases). Dov shareholders would receive $2mm in cash, and Euthymics would pay for some of Dov's outstanding expenses.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Reverse Acquisition
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies